Novo’s Wegovy touts obesity-treating potential in patients as young as six

There are currently limited weight loss therapeutic options indicated for use in patients with obesity aged between six and 12 years old. There are currently limited weight loss therapeutic options indicated for use in patients aged between six and 12 years old. There are currently limited pharmaceutical treatment options for patients with obesity under 12 years of age. Credit: New Africa / Shutterstock.com. Novo Nordisk’s blockbuster weight loss drug, Wegovy (semaglutide), has met its primary endpoint in a Phase III post-marketing study in children with obesity – highlighting the drug’s potential to take younger patients under the obesity threshold when…

Source: Clinical Trials Arena